Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zai Lab Approved to Launch Novel Antibiotic in China for Pneumonia

publication date: Dec 17, 2021

Shanghai Zai Lab was approved in China to launch Nuzyra® (omadacycline), a novel antibiotic available in oral and intravenous formulations, to treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Nuzyra was designed to overcome tetracycline resistance and improve treatment in several bacterial infections. In 2017, Zai acquired greater China rights to the antibiotic from Paratek Pharma of Boston. It made a $7.5 million upfront payment and is responsible for unspecified milestones plus royalties. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688)

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital